GOSSAMER BIO, INC. Operating Income
GOSSAMER BIO, INC. (GOSS) reported Operating Income of -$26.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- GOSSAMER BIO, INC. operating income (loss) for the quarter ending 2026-06-30 was -$26.07M.
- GOSSAMER BIO, INC. operating income (loss) for the quarter ending 2026-03-31 was -$44.87M.
- GOSSAMER BIO, INC. operating income (loss) for the quarter ending 2025-12-31 was -$46.04M.
- GOSSAMER BIO, INC. operating income (loss) for the quarter ending 2025-09-30 was -$49.11M.
- GOSSAMER BIO, INC. operating income (loss) for fiscal 2025 was -$170.73M.
- GOSSAMER BIO, INC. operating income (loss) for fiscal 2024 was -$59.92M.
- GOSSAMER BIO, INC. operating income (loss) for fiscal 2023 was -$183.76M.
- GOSSAMER BIO, INC. operating income (loss) for fiscal 2022 was -$218.59M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$26.07M 10-Q · filed 2026-08-13 | -$70.94M 10-Q · filed 2026-08-13 | -$116.98M derived: sum of 3 quarters · filed 2026-08-13 | -$166.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$44.87M 10-Q · filed 2026-05-15 | -$90.91M derived: sum of 2 quarters · filed 2026-05-15 | -$140.02M derived: sum of 3 quarters · filed 2026-05-15 | -$178.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$46.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$95.15M derived: sum of 2 quarters · filed 2026-03-17 | -$133.92M derived: sum of 3 quarters · filed 2026-08-13 | -$170.73M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$49.11M 10-Q · filed 2025-11-05 | -$87.88M derived: sum of 2 quarters · filed 2026-08-13 | -$124.69M 10-Q · filed 2025-11-05 | -$160.82M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$38.77M 10-Q · filed 2026-08-13 | -$75.58M 10-Q · filed 2026-08-13 | -$111.70M derived: sum of 3 quarters · filed 2026-08-13 | -$145.62M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$36.81M 10-Q · filed 2026-05-15 | -$72.94M derived: sum of 2 quarters · filed 2026-05-15 | -$106.86M derived: sum of 3 quarters · filed 2026-05-15 | -$54.77M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | -$36.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$70.05M derived: sum of 2 quarters · filed 2026-03-17 | -$17.96M derived: sum of 3 quarters · filed 2026-03-17 | -$59.92M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$33.92M 10-Q · filed 2025-11-05 | $18.17M derived: sum of 2 quarters · filed 2025-11-05 | -$23.79M 10-Q · filed 2025-11-05 | -$72.82M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $52.09M 10-Q · filed 2025-08-05 | $10.13M 10-Q · filed 2025-08-05 | -$38.90M derived: sum of 3 quarters · filed 2026-03-17 | -$79.39M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | -$41.96M 10-Q · filed 2025-05-15 | -$90.99M derived: sum of 2 quarters · filed 2026-03-17 | -$131.48M derived: sum of 3 quarters · filed 2026-03-17 | -$177.78M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$49.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$89.52M derived: sum of 2 quarters · filed 2026-03-17 | -$135.82M derived: sum of 3 quarters · filed 2026-03-17 | -$183.76M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$40.49M 10-Q · filed 2024-11-07 | -$86.79M derived: sum of 2 quarters · filed 2024-11-07 | -$134.73M 10-Q · filed 2024-11-07 | -$189.09M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | -$46.30M 10-Q · filed 2024-08-12 | -$94.24M 10-Q · filed 2024-08-12 | -$148.60M derived: sum of 3 quarters · filed 2025-03-13 | -$204.62M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | -$47.94M 10-Q · filed 2024-05-07 | -$102.30M derived: sum of 2 quarters · filed 2025-03-13 | -$158.32M derived: sum of 3 quarters · filed 2025-03-13 | -$212.19M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | -$54.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$110.38M derived: sum of 2 quarters · filed 2025-03-13 | -$164.25M derived: sum of 3 quarters · filed 2025-03-13 | -$218.59M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$56.02M 10-Q · filed 2023-11-09 | -$109.89M derived: sum of 2 quarters · filed 2023-11-09 | -$164.24M 10-Q · filed 2023-11-09 | -$215.90M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$53.87M 10-Q · filed 2023-08-08 | -$108.22M 10-Q · filed 2023-08-08 | -$159.88M derived: sum of 3 quarters · filed 2024-03-05 | -$215.54M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | -$54.34M 10-Q · filed 2023-05-09 | -$106.00M derived: sum of 2 quarters · filed 2024-03-05 | -$161.67M derived: sum of 3 quarters · filed 2024-03-05 | -$217.26M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | -$51.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$107.33M derived: sum of 2 quarters · filed 2024-03-05 | -$162.92M derived: sum of 3 quarters · filed 2024-03-05 | -$216.12M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$55.66M 10-Q · filed 2022-11-03 | -$111.26M derived: sum of 2 quarters · filed 2022-11-03 | -$164.46M 10-Q · filed 2022-11-03 | -$224.55M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | -$55.60M 10-Q · filed 2022-08-09 | -$108.80M 10-Q · filed 2022-08-09 | -$168.89M derived: sum of 3 quarters · filed 2023-03-17 | -$222.46M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | -$53.20M 10-Q · filed 2022-05-10 | -$113.29M derived: sum of 2 quarters · filed 2023-03-17 | -$166.86M derived: sum of 3 quarters · filed 2023-03-17 | -$232.20M derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | -$60.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$113.66M derived: sum of 2 quarters · filed 2023-03-17 | -$179.00M derived: sum of 3 quarters · filed 2023-03-17 | -$233.96M 10-K · filed 2023-03-17 |
| 2020-09-30 | -$53.57M 10-Q · filed 2021-11-08 | -$118.91M derived: sum of 2 quarters · filed 2021-11-08 | -$173.88M 10-Q · filed 2021-11-08 | -$229.66M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$65.34M 10-Q · filed 2021-08-09 | -$120.31M 10-Q · filed 2021-08-09 | -$176.09M derived: sum of 3 quarters · filed 2021-08-09 | -$226.08M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | -$54.97M 10-Q · filed 2021-05-06 | -$110.75M derived: sum of 2 quarters · filed 2021-05-06 | -$160.74M derived: sum of 3 quarters · filed 2021-05-06 | -$207.09M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$55.79M 10-K · filed 2020-03-24 | -$105.77M derived: sum of 2 quarters · filed 2020-11-10 | -$152.12M derived: sum of 3 quarters · filed 2020-11-10 | -$186.14M 10-K · filed 2022-03-03 |
| 2019-09-30 | -$49.99M 10-Q · filed 2020-11-10 | -$96.33M derived: sum of 2 quarters · filed 2020-11-10 | -$130.35M 10-Q · filed 2020-11-10 | -$170.16M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$46.35M 10-Q · filed 2020-08-11 | -$80.37M 10-Q · filed 2020-08-11 | -$120.17M derived: sum of 3 quarters · filed 2020-08-11 | -$170.20M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | -$34.02M 10-Q · filed 2020-05-12 | -$73.82M derived: sum of 2 quarters · filed 2020-05-12 | -$123.85M derived: sum of 3 quarters · filed 2020-05-12 | -$156.88M derived: sum of 4 quarters · filed 2020-05-12 |
| 2018-12-31 | -$39.81M 10-K · filed 2020-03-24 | -$89.83M derived: sum of 2 quarters · filed 2020-03-24 | -$122.87M derived: sum of 3 quarters · filed 2020-03-24 | -$148.99M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$50.02M 10-K · filed 2020-03-24 | -$83.06M derived: sum of 2 quarters · filed 2020-03-24 | -$109.19M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$33.04M 10-K · filed 2020-03-24 | -$59.16M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$26.13M 10-K · filed 2020-03-24 | |||
| 2017-12-31 | -$6.65M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |